HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – HC Wainwright decreased their Q1 2026 earnings estimates for shares of Immunic in a report issued on Monday, March 2nd. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.08) EPS.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02).

Several other brokerages have also recently issued reports on IMUX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. D. Boral Capital decreased their target price on Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Roth Mkm initiated coverage on Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 target price on the stock. Brookline Capital Acquisition raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.00.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.07 on Wednesday. The stock has a market cap of $139.59 million, a price-to-earnings ratio of -1.53 and a beta of 1.46. Immunic has a 12 month low of $0.51 and a 12 month high of $1.35. The stock’s 50 day moving average price is $0.72 and its 200 day moving average price is $0.76.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently modified their holdings of IMUX. Nantahala Capital Management LLC purchased a new position in Immunic in the 4th quarter worth about $2,337,000. Vanguard Group Inc. boosted its holdings in shares of Immunic by 5.3% in the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after buying an additional 219,957 shares during the period. Laurion Capital Management LP increased its position in shares of Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after acquiring an additional 2,000,000 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares during the period. Finally, Focus Partners Wealth lifted its position in shares of Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after acquiring an additional 39,063 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Key Stories Impacting Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts (Q3 & Q4 2026 and FY2026/FY2027 improvements) and kept a Buy rating, which supports a constructive near‑term view on reducing expected losses. Details here: MarketBeat: IMUX coverage
• Neutral Sentiment: Management will present at investor conferences in March (Leerink Partners Global Healthcare Conference, March 8–11). Conference participation increases investor access and could catalyze new analyst or institutional interest but does not guarantee clinical or financial news. Immunic to Participate in Investor Conferences in March
• Negative Sentiment: HC Wainwright cut its price target from $8 to $5.0 (still a Buy) and trimmed several longer‑term EPS forecasts (notably FY2028 and FY2029), which can exert downward pressure on the stock because it reduces upside expectations and signals lower long‑term profitability. Coverage of the PT cut here: HC Wainwright Lowers Immunic Price Target to $5.00
• Negative Sentiment: HC Wainwright also lowered some near‑term quarter estimates (Q1 and Q2 2026 were revised lower), increasing short‑term execution risk and potential for additional downside if upcoming results miss the revised figures. Summary reporting: Benzinga coverage

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.